The FY20 Defense Appropriations Act provides funding to the Department of Defense Lupus Research Program (LRP) to support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY20 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
Applications submitted to the FY20 LRP Idea Award and/or Impact Award must address one or more of the following Focus Areas:
- · Understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies
- · Understanding lupus disease heterogeneity including, but not limited to, strategies and technologies to subtype patients and understanding lupus disease mechanisms
- · Improving quality of life for individuals living with lupus including, but not limited to, access to healthcare resources, outcome research, symptom control, comparative effectiveness research, and issues and challenges that when addressed make day-to-day living with lupus easier and life more fulfilling
- · Understanding how the underlying genetic components and gene-environment interactions of lupus relate to clinical disease characteristics using functional genomic studies
- · Determining the pathobiology of lupus disease in target human tissues including, but not limited to, imagining studies, genomics of lupus in particular tissues, and metabolomics
Applications submitted to the FY20 LRP Transformative Vision Award must address the following Focus Area:
- · Improving quality of life for individuals living with lupus including, but not limited to, access to healthcare resources, outcome research, symptom control, comparative effectiveness research, and issues and challenges that when addressed make day-to-day living with lupus easier and life more fulfilling
https://cdmrp.army.mil/funding/lrp
Idea Award – Letter of Intent Due August 25, 2020
All investigators at or above the level of postdoctoral fellow (or equivalent)
· Supports highly innovative, untested, potentially groundbreaking ideas in lupus research.
· Emphasis is on innovation
· Must address one of the Fiscal Year 2020 (FY20) LRP Focus Areas
· Clinical trials are not allowed
· Preliminary data are not required
· The maximum allowable funding for the entire period of performance is in total costs
· The maximum period of performance is 2 years
Impact Award – Letter of Intent is Due August 25, 2020
Investigators at or above the level of Assistant Professor (or equivalent)
· Supports innovative, high-risk/high-reward research
· Emphasis is on impact
· Must address one of the FY20 LRP Focus Areas
· Clinical trials are not allowed
· Preliminary data are encouraged but not required
· The maximum allowable funding for the entire period of performance is $750,000 in total costs.
· The maximum period of performance is 4 years
Transformative Vision Award – Letter of Intent due August 25, 2020
Independent Investigators at or above the level of Assistant Professor (or equivalent)
· Supports high-risk, high-reward studies that have the potential to make a significant near-term impact on the quality of life of lupus patients
· Emphasis is on near-term impact to quality of life
· Must address the FY20 LRP TVA Focus Areas
· Clinical trials are allowed
· Animal studies are not allowed
· Preliminary data are required
· The maximum allowable funding for the entire period of performance is $2,500,000 in total costs
· The maximum period of performance is 4 years
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507
help@eBrap.org
